Alnylam Names TTR Amyloidosis Rx as Next IND Candidate, Posts Higher Q2 Losses on Increased Costs | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals last week announced that it has advanced its preclinical TTR amyloidosis therapeutic candidate into its formal drug-development pipeline, aiming to file an investigational new drug application on the systemically administered drug by the end of 2009.

The company made the disclosure as part of an announcement of its second-quarter financial results, which included a roughly 77 percent jump in net loss as research and development spending swelled more than 30 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.